Edwards’ Longtime TAVR Leader is Named PROCEPT BioRobotics CEO

PROCEPT BioRobotics has recruited 18-year Edwards Lifesciences TAVR executive Larry L. Wood as its new president and CEO, effective Sept. 2. He succeeds the retiring Dr. Reza Zadno.

Dr. Zadno has led the company since 2020 through significant growth and commercial expansion, including adoption and utilization of Aquablation therapy for BPH treatment, PROCEPT BioRobotics’ successful 2021 public offering, and the start of clinical trials for prostate cancer treatment.

“On behalf of the board of directors, I want to thank Reza for his dedication to the company and its mission over the past five years,” PROCEPT BioRobotics Board Chair Thomas M. Prescott said. “Reza’s deep understanding of the potential of the company’s technology to redefine the standard of care for BPH and steadfast leadership through key milestones have paved the way for even greater growth and opportunity ahead.”

“The last five years have been among the most rewarding of my career and I am very proud of what our team has achieved,” Dr. Zadno added. “We grew the number of global Aquablation procedures from a few hundred to nearly 100,000, raised more than $600 million capital to support our continued growth, significantly increased enterprise value, and most importantly, we have changed the treatment landscape for patients suffering from BPH and the doctors who treat them. We are just scratching the surface of what’s possible, and I am thrilled to pass the torch to Larry Wood to lead the next phases of the company’s journey.”

Wood is an accomplished executive leader with more than 40 years of experience in the medical technology industry at both Edwards Lifesciences and Baxter Healthcare Corporation. He is joining PROCEPT BioRobotics from Edwards, where he has served as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart, since 2023. Prior to that, he was corporate vice president, Transcatheter Aortic Valve Replacement and earlier in his career at Edwards, he held key positions in manufacturing management, regulatory affairs, and strategic and clinical marketing, primarily in the company’s leading surgical heart valve franchise. In 2024, he joined PROCEPT BioRobotics’ Board of Directors and is a member of its audit committee.

Wood earned an MBA from Pepperdine Graziadio Business School.

“Larry’s strengths and vast experience in the medical technology industry are a great fit with the opportunities ahead for PROCEPT BioRobotics. Larry has demonstrated outstanding leadership and business acumen in one of the most clinically demanding medical device product categories and is known for championing technologies that can significantly benefit patients,” Prescott stated. “At Edwards, Larry and his team revolutionized how patients with severe aortic stenosis are treated. We are excited to have Larry join the company as CEO, especially after having the opportunity to get to know him, his leadership style, and his insights during his tenure on the PROCEPT BioRobotics board.”

“I am honored to join PROCEPT BioRobotics at such a pivotal time in the company’s growth,” Wood commented. “The company’s approach to treating prostate disorders has the potential to transform the standard of care for patients worldwide. I look forward to leading this team and building on their many successes to continue to improve treatment outcomes for doctors and their patients.”

PROCEPT BioRobotics’ aims to revolutionize BPH treatment globally in partnership with urologists by delivering robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million U.S. men. The company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.